Do analysts rate THAR or EVAX?

Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 238.46%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is THAR or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Evaxion A/S N/A -73.56% -37.45%

Is BMEA or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Evaxion A/S N/A -73.56% -37.45%

Is EVAX or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Black Diamond Therapeutics N/A -30.18% -23.91%

Evaxion A/S (EVAX) Competitors

$3.25 -0.06 (-1.81%)

Closing price 07/8/2026 03:59 PM Eastern

Extended Trading

$3.15 -0.10 (-3.20%)

As of 07:57 AM Eastern

Compare

EVAX vs. THAR, FTLF, ATRA, BMEA, and BDTX

Should you buy Evaxion A/S stock or one of its competitors? MarketBeat compares Evaxion A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evaxion A/S include Tharimmune (THAR), FitLife Brands (FTLF), Atara Biotherapeutics (ATRA), Biomea Fusion (BMEA), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Evaxion A/S compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evaxion A/S's return on equity of -73.56% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 238.46%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Evaxion A/S	Neutral

Evaxion A/S has higher revenue and earnings than Tharimmune. Evaxion A/S is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Evaxion A/S	$7.53M	3.60	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats Tharimmune on 10 of the 12 factors compared between the two stocks.

How does Evaxion A/S compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 61.7% of FitLife Brands shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, FitLife Brands' average media sentiment score of 0.00 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
FitLife Brands	Neutral
Evaxion A/S	Neutral

FitLife Brands has higher revenue and earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.25	$6.33M	$0.60	18.10
Evaxion A/S	$7.53M	3.60	-$7.71M	-$1.47	N/A

FitLife Brands presently has a consensus price target of $21.50, suggesting a potential upside of 97.97%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 238.46%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts plainly believe Evaxion A/S is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

FitLife Brands has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

FitLife Brands has a net margin of 6.64% compared to Evaxion A/S's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Evaxion A/S	N/A	-73.56%	-37.45%

Summary

FitLife Brands beats Evaxion A/S on 8 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Atara Biotherapeutics?

Evaxion A/S (NASDAQ:EVAX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Evaxion A/S has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Evaxion A/S. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.60	-$7.71M	-$1.47	N/A
Atara Biotherapeutics	$120.77M	0.72	$32.69M	-$0.67	N/A

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 1 mentions for Atara Biotherapeutics and 0 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.00 equaled Atara Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Evaxion A/S	Neutral
Atara Biotherapeutics	Neutral

Evaxion A/S presently has a consensus target price of $11.00, suggesting a potential upside of 238.46%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential downside of 1.55%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Evaxion A/S is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Evaxion A/S has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Evaxion A/S's return on equity of -73.56% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Summary

Evaxion A/S beats Atara Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Evaxion A/S has higher revenue and earnings than Biomea Fusion. Evaxion A/S is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Evaxion A/S	$7.53M	3.60	-$7.71M	-$1.47	N/A

Evaxion A/S's return on equity of -73.56% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Evaxion A/S	N/A	-73.56%	-37.45%

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

In the previous week, Biomea Fusion had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 1 mentions for Biomea Fusion and 0 mentions for Evaxion A/S. Biomea Fusion's average media sentiment score of 0.00 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
Biomea Fusion	Neutral
Evaxion A/S	Neutral

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 553.85%. Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 238.46%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Biomea Fusion beats Evaxion A/S on 7 of the 13 factors compared between the two stocks.

How does Evaxion A/S compare to Black Diamond Therapeutics?

Evaxion A/S (NASDAQ:EVAX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Black Diamond Therapeutics has higher revenue and earnings than Evaxion A/S. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.60	-$7.71M	-$1.47	N/A
Black Diamond Therapeutics	$70M	1.56	$22.37M	-$0.77	N/A

Black Diamond Therapeutics' return on equity of -30.18% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for Evaxion A/S. Black Diamond Therapeutics' average media sentiment score of 1.90 beat Evaxion A/S's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evaxion A/S	Neutral
Black Diamond Therapeutics	Very Positive

Evaxion A/S presently has a consensus price target of $11.00, indicating a potential upside of 238.46%. Black Diamond Therapeutics has a consensus price target of $9.83, indicating a potential upside of 417.54%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Evaxion A/S on 13 of the 16 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVAX vs. The Competition

Export

Metric	Evaxion A/S	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.61M	$1.83B	$6.98B	$12.46B
Dividend Yield	N/A	N/A	2.67%	7.39%
P/E Ratio	-2.21	76.12	27.13	24.24
Price / Sales	3.60	7.29	535.63	96.53
Price / Cash	N/A	26.15	49.24	56.96
Price / Book	1.59	5.65	10.96	6.38
Net Income	-$7.71M	-$54.76M	$3.56B	$331.19M
7 Day Performance	-4.69%	0.70%	-0.09%	-1.35%
1 Month Performance	-10.47%	3.61%	5.22%	1.24%
1 Year Performance	27.95%	-4.77%	30.29%	20.72%

Evaxion A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVAX Evaxion A/S	2.2411 of 5 stars	$3.25 -1.8%	$11.00 +238.5%	+31.0%	$27.61M	$7.53M	N/A	60
THAR Tharimmune	N/A	$2.78 -6.4%	N/A	+42.0%	$104.89M	N/A	N/A	2
FTLF FitLife Brands	4.3748 of 5 stars	$11.01 -0.5%	$21.50 +95.3%	-19.6%	$103.86M	$81.46M	18.23	20
ATRA Atara Biotherapeutics	0.7171 of 5 stars	$11.48 +2.8%	$9.50 -17.2%	+4.1%	$100.64M	$120.77M	N/A	330	Gap Down
BMEA Biomea Fusion	1.9587 of 5 stars	$1.47 +5.8%	$8.50 +478.2%	-30.1%	$100.50M	N/A	N/A	50	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVAX) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evaxion A/S (EVAX) Competitors

EVAX vs. THAR, FTLF, ATRA, BMEA, and BDTX

How does Evaxion A/S compare to Tharimmune?

Summary

How does Evaxion A/S compare to FitLife Brands?

Summary

How does Evaxion A/S compare to Atara Biotherapeutics?

Summary

How does Evaxion A/S compare to Biomea Fusion?

Summary

How does Evaxion A/S compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evaxion A/S (EVAX) Competitors

EVAX vs. THAR, FTLF, ATRA, BMEA, and BDTX

How does Evaxion A/S compare to Tharimmune?

Do insiders and institutionals have more ownership in THAR or EVAX?

Is THAR or EVAX more profitable?

Do analysts rate THAR or EVAX?

Which has more volatility & risk, THAR or EVAX?

Does the media prefer THAR or EVAX?

Which has higher earnings and valuation, THAR or EVAX?

Summary

How does Evaxion A/S compare to FitLife Brands?

Do insiders & institutionals have more ownership in FTLF or EVAX?

Does the media refer more to FTLF or EVAX?

Which has higher valuation & earnings, FTLF or EVAX?

Do analysts rate FTLF or EVAX?

Which has more volatility and risk, FTLF or EVAX?

Is FTLF or EVAX more profitable?

Summary

How does Evaxion A/S compare to Atara Biotherapeutics?

Which has more volatility and risk, EVAX or ATRA?

Which has higher earnings & valuation, EVAX or ATRA?

Does the media favor EVAX or ATRA?

Do analysts prefer EVAX or ATRA?

Do insiders and institutionals have more ownership in EVAX or ATRA?

Is EVAX or ATRA more profitable?

Summary

How does Evaxion A/S compare to Biomea Fusion?

Which has stronger earnings & valuation, BMEA or EVAX?

Is BMEA or EVAX more profitable?

Do insiders & institutionals believe in BMEA or EVAX?

Which has more volatility & risk, BMEA or EVAX?

Does the media refer more to BMEA or EVAX?

Do analysts prefer BMEA or EVAX?

Summary

How does Evaxion A/S compare to Black Diamond Therapeutics?

Which has stronger valuation and earnings, EVAX or BDTX?

Is EVAX or BDTX more profitable?

Do institutionals & insiders have more ownership in EVAX or BDTX?

Does the media favor EVAX or BDTX?

Do analysts rate EVAX or BDTX?

Which has more volatility and risk, EVAX or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools